Compare Rigetti Computing Inc (RGTI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Sanofi SA — how do they compare? Rigetti Computing Inc trades at $15.21 (market cap $5.08B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 20.6× Rigetti Computing Inc's market cap, and Sanofi SA pays a 5.53% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| RGTI | SNY | |
|---|---|---|
Market Cap | $5.08B | $104.85B |
Sector | Technology | Health |
52-Week High | $56.34 | $52.34 |
52-Week Low | $12.90 | $41.33 |
Enterprise Value | $4.67B | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, while showing bearish technical signals with 17 sell indicators versus 5 buy signals. The company maintains strong analyst support with 85.7% buy ratings and a $32.67 consensus price target, despite posting significant losses (-$216.21M net income) and negative margins. Recent news highlights Rigetti's $569M cash position and government contracts supporting its quantum computing roadmap.
RGTI offers substantial upside potential based on analyst targets but carries high risk due to persistent losses and negative profitability metrics. The stock's investment thesis hinges on successful quantum technology commercialization, with current valuation reflecting speculative growth expectations rather than fundamental performance.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
